Listed by the USPTO as LADD, CAROLYN LOUISE
Tech Center 1600 • Art Units: 1622 1629
This examiner grants 59% of resolved cases
LADD, CAROLYN LOUISE works in tech center 1600 and art unit 1622. The profile covers 87 resolved cases, with an allowance rate of 58.6% and a median of 1307 days to allowance. The interview lift is 47.1%, indicating a positive association between interviews and allowance outcomes in the reported cases.
The listed companies are Tango Therapeutics Inc., Novartis AG, and University of Basel. The listed firms include GOODWIN PROCTER LLP, ArentFox Schiff, LLP & DFCI, and Clark+Elbing LLP - Revolution Medicines, Inc. The interview measure supports considering direct examiner engagement in prosecution planning.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18730975 | RIBOCICLIB PHARMACEUTICAL COMPOSITIONS | Non-Final OA | Novartis AG |
| 17621057 | HCK DEGRADERS AND USES THEREOF | Final Rejection | DANA-FARBER CANCER INSTITUTE, INC. |
| 18833468 | COMPOUNDS AND METHODS OF USE | Non-Final OA | Tango Therapeutics, Inc. |
| 18833315 | COMPOUNDS AND METHODS OF USE | Non-Final OA | Tango Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy58.6% of resolved applications examined by Carolyn Louise Ladd were allowed (87 resolved cases), compared with 60.6% across Art Unit 1622 over the last five years.
This examiner's interview lift is +47.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Carolyn Louise Ladd took 1,307 days on average from filing to allowance.
Carolyn Louise Ladd examines applications in Art Unit 1622 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
